Lung cancer requires multidisciplinary treatment to improve patient survival: A case report

Pezzuto,Aldo; Terzo,Fabrizio; Graziani,Maria Laura; Ricci,Alberto; Bruno,Pierdonato; Mariotta,Salvatore

doi:10.3892/ol.2017.6511

Lung cancer requires multidisciplinary treatment to improve patient survival: A case report

Authors:
- Aldo Pezzuto
- Fabrizio Terzo
- Maria Laura Graziani
- Alberto Ricci
- Pierdonato Bruno
- Salvatore Mariotta
View Affiliations

Affiliations: Department of Cardiovascular and Thoracic Disease, Division of Pulmonology, St. Andrew's Hospital, I‑00189 Rome, Italy, Department of Clinical and Molecular Medicine, Sapienza University of Rome, I‑00189 Rome, Italy
Published online on: June 30, 2017 https://doi.org/10.3892/ol.2017.6511
Pages: 3035-3038

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study reports two cases of lung cancer with the involvement of the pleura. The diagnosis of adenocarcinoma with epidermal growth factor receptor (EGFR) mutation was made following repeated thoracentesis with cytology of pleural fluid and thoracoscopy with pleural biopsies. Talc pleurodesis was successfully performed in both cases subsequent to diagnosis. Following talc pleurodesis, the first patient (62 years old; male; non‑smoker) underwent 3 cycles of cisplatin/vinorelbine chemotherapy, with a poor response. Concurrently, due to the presence of an EGFR mutation, treatment with gefitinib was initiated, with the patient achieving a good response for ~12 months. The residual tumor was treated with stereotactic radiotherapy and the patient continued gefitinib treatment. The patient is presently in good health, has not exhibited any signs of relapse and is continuing gefitinib treatment without side effects. The second patient (53 years old; male ex‑smoker) underwent treatment with gefitinib subsequent to talc pleurodesis for a total of 15 months. In addition, radiotherapy (60 Gy) on the residual lesion was performed. Subsequently, second‑line therapy with cisplatin/premetrexed was prescribed and followed by maintenance treatment with premetrexed. Three years after diagnosis, the patient did not exhibit any signs of recurrence. These two cases highlight the difficulty in treating advanced stage lung cancer, despite the presence of EGFR mutation. Each lung cancer is different and requires the physician to possess a wide range of knowledge of the therapeutic options available, in addition to careful monitoring in order to adjust the treatment over time. A multidisciplinary approach, involving surgeons, radiation oncologists, pulmonologists and oncologists, is required to optimize the survival and quality of life of patients with lung cancer.

View Figures

View References

1	Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, et al: NCCN guidelines insights: Non-Small cell lung cancer, version 4.2016. J Natl Compr Canc Netw. 14:255–264. 2016. View Article : Google Scholar : PubMed/NCBI
2	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:pp. 584–594. 2008; View Article : Google Scholar : PubMed/NCBI
3	Xiao HQ, Tian RH, Zhang ZH, Du KQ and Ni YM: Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: A systematic review and meta-analysis. Onco Targets Ther. 9:1471–1476. 2016.PubMed/NCBI
4	Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et al: PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 31:2895–2902. 2013. View Article : Google Scholar : PubMed/NCBI
5	Li G, Gao S, Sheng Z and Li B: The efficacy of single-agent epidermal growth factor receptor tyrosine kinase inhibitor therapy in biologically selected patients with non-small-cell lung cancer: A meta-analysis of 19 randomized controlled trials. Chemotherapy. 61:179–189. 2016. View Article : Google Scholar : PubMed/NCBI
6	Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
7	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
8	Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
9	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
10	Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
11	Yang JC, Sequist LV, Zhou C, Schuler M, Geater SL, Mok T, Hu CP, Yamamoto N, Feng J, O'Byrne K, et al: Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol. 27:2103–2110. 2016. View Article : Google Scholar : PubMed/NCBI
12	Zimmer PW, Hill M, Casey K, Harvey E and Low DE: Prospective randomized trial of talc slurry vs bleomycin in pleurodesis for syntomatic malignant pleural effusions. Chest. 112:430–434. 1997. View Article : Google Scholar : PubMed/NCBI
13	Cox SE and Katlic MR: Non-intubated video-assisted thoracic surgery as the modality of choice for treatment of recurrent pleural effusions. Ann Transl Med. 3:1032015.PubMed/NCBI
14	Rodriguez-Panadero F, Janssen JP and Astoul P: Thoracoscopy: General overview and place in the diagnosis and management of pleural effusion. Eur Resp J. 28:409–422. 2006. View Article : Google Scholar
15	Xia H, Wang XJ, Zhou Q, Shi HZ and Tong ZH: Efficacy and safety of talc pleurodesis for malignant pleural effusion: A meta-analysis. PLoS One. 9:e870602014. View Article : Google Scholar : PubMed/NCBI
16	Rami-Porta R, Asamura H, Travis WD and Rusch VW: Lung cancer-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 67:138–155. 2017. View Article : Google Scholar : PubMed/NCBI
17	Baker S, Dahele M, Lagerwaard F and Senan S: A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol. 11:1152016. View Article : Google Scholar : PubMed/NCBI
18	Dupic G and Bellière-Calandry A: Non-small cell lung cancer irradiation in elderly. Cancer Radiother. 20:322–329. 2016. View Article : Google Scholar : PubMed/NCBI
19	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
20	Zappa C and Mousa SA: Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
21	Bearz A, Passalacqua R, Alabiso O, Cinieri S, Gridelli C, Cravesana C and Crinò L: First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer: Analysis of the Italian patients enrolled in the SAiL study. Clin Drug Investig. 32:755–760. 2012. View Article : Google Scholar : PubMed/NCBI